CI Scientists

🚀 Exciting Developments in Antibody Drug Conjugates! 🔬 🔔 Follow our page for interesting ADC updates! 🌟 Explore the latest edition of ADC Digest for this week of October 2024, featuring groundbreaking advancements in the field of Antibody Drug Conjugates. 💊Merck and Astellas/Pfizer’s bladder cancer combination receives MHRA approval 💊SystImmune, Inc. announces FDA clearance of IND application for BL-M11D1 in relapsed/refractory Acute Myeloid Leukemia 💊BlissBio receives IND approval from FDA for novel ADC BB-1712 💊ENHERTU approved in China as first HER2 directed therapy for patients with HER2 mutant metastatic non-small cell lung cancer #ADC #MedicalInnovations #Innovation #ADCnews #CIScientists #Antibodydrugconjugate #cancer #competitiveintelligence

We are hiring once again! If you are a recent Ph.D., M.Pharm, or M.Sc., and looking to start your career, please share your CV at hr@ciscientists.com Please feel free to share this opportunity with anyone who may be interested. Thank you! #Hiring #CareerOpportunities #FreshTalent #CIScientists

🚀 Exciting Developments in Antibody Drug Conjugates! 🔬 🔔 Follow our page for interesting ADC updates! 🌟 Explore the latest edition of ADC Digest for this week of October 2024, featuring groundbreaking advancements in the field of Antibody Drug Conjugates. 💊Ono enters into license agreement for LCB97, an Antibody-Drug Conjugate, and research collaboration and license agreement to generate novel ADC candidates by leveraging ConjuAll ADC platform with LigaChem Biosciences 💊MediLink Therapeutics and Amgen announce global clinical collaboration to evaluate combination therapy for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) 💊FDA gives Adcendo green light to trial ADC in Phase I/II sarcoma study 💊CSPC Pharmaceutical announces CPO301 receives Fast Track Designation (FTD) from US FDA 💊AstraZeneca’s dual-antibody ADC approved for two clinical trials in China #ADC #MedicalInnovations #Innovation #ADCnews #CIScientists #Antibodydrugconjugate #cancer #competitiveintelligence

At CI Scientists, we believe that mental well-being is at the heart of both personal and professional growth. By nurturing a supportive environment, we empower creativity, resilience, and progress. Take a moment today to prioritize your mental health—because caring for your mind is just as important as the work we do. #MentalHealthMatters #MindfulLiving #CIScientists #MentalWellness #WorldMentalHealthDay #SelfCareMatters #WellbeingAtWork

🚀 Exciting Developments in Antibody Drug Conjugates! 🔬 🔔 Follow our page for interesting ADC updates! 🌟 Explore the latest edition of ADC Digest for this week of October 2024, featuring groundbreaking advancements in the field of Antibody Drug Conjugates. 💊EMA recommends approval of Mirvetuximab Soravtansine for marketing authorization 💊Enhertu receives priority review in the US for HER2-Low and HER2-Ultralow metastatic breast cancer patients previously treated with endocrine therapy 💊Alphamab Oncology and CSPC enter licensing agreement for Anti-HER2 bispecific ADC JSKN003 💊Alentis Therapeutics secures FDA IND approval for ALE.P02, an innovative CLDN1-ADC targeting squamous cancers #ADC #MedicalInnovations #Innovation #ADCnews #CIScientists #Antibodydrugconjugate #cancer #competitiveintelligence

Stand strong, spread hope. Fight breast cancer! #BreastCancerAwareness #BreastCancerResearch #EarlyDetectionSavesLives #CIScientists

🚀 Exciting Developments in Antibody Drug Conjugates! 🔬 🔔 Follow our page for interesting ADC updates! 🌟 Explore the latest edition of ADC Digest for this week of September 2024, featuring groundbreaking advancements in the field of Antibody Drug Conjugates. 💊Araris Biotech AG Expands its IP Portfolio with the Acquisition of Innate Pharma’s Portfolio of Transglutaminase Patents for the Generation of ADC's 💊AstraZeneca, Daiichi Sankyo’s ADC Flops in Phase III Breast Cancer on Heels of Lung Cancer Stumble 💊Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors 💊Pinotbio Secures Milestone Payment Following Celltrion’s Execution of ADC Platform Technology Option 💊FDA Grants Fast Track Status to EO-3021 for CLDN18.2-Expressing Gastric or GEJ Cancer #ADC #MedicalInnovations #Innovation #ADCnews #CIScientists #Antibodydrugconjugate #cancer #competitiveintelligence

On #WorldAlzheimersDay, we at CI Scientists stand in solidarity with the global community in raising awareness and advancing research to combat Alzheimer's disease. #WorldAlzheimersDay #AlzheimersAwareness #CIScientists

🚀 Exciting Developments in Antibody Drug Conjugates! 🔬 🔔 Follow our page for interesting ADC updates! 🌟 Explore the latest edition of ADC Digest for this week of September 2024, featuring groundbreaking advancements in the field of Antibody Drug Conjugates. 💊 Daiichi Sankyo-Merck’s ‘guided-missile’ cancer drug meets main goal in late-stage trial 💊 Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference 💊Approval Sought for Belantamab Mafodotin Combos for R/R Multiple Myeloma in Japan #ADC #MedicalInnovations #Innovation #ADCnews #CIScientists #Antibodydrugconjugate #cancer #competitiveintelligence

🚀 Exciting Developments in Antibody Drug Conjugates! 🔬 🔔 Follow our page for interesting ADC updates! 🌟 Explore the latest edition of ADC Digest for this week of September 2024, featuring groundbreaking advancements in the field of Antibody Drug Conjugates. 💊OS Therapies announces positive efficacy and safety data for ovarian cancer therapeutic candidate developed based on tunable antibody drug conjugate (tADC) platform using proprietary silicone linker platform in preclinical models 💊Merck launches single-use reactor designed to accelerate antibody drug conjugate manufacturing 💊Antibody-Drug Conjugate I-DXd shows clinically meaningful response in patients with extensive-stage small cell lung cancer 💊AstraZeneca, Daiichi Sankyo’s Dato-DXd fails to significantly improve overall survival in phase III NSCLC 💊AstraZeneca/Daiichi’s ADC shows better survival for nonsquamous NSCLC patients #ADC #MedicalInnovations #Innovation #ADCnews #CIScientists #Antibodydrugconjugate #cancer #competitiveintelligence